Monograph of Nystatin

Introduction/Overview

Nystatin is a polyene macrolide antifungal that has been employed for decades to manage superficial Candida infections. Its clinical relevance stems from its broad spectrum against yeast species, low systemic toxicity, and availability in multiple formulations tailored to topical, oral, and prophylactic indications. The importance of mastering nystatin pharmacology lies in optimizing therapeutic outcomes while minimizing adverse events, particularly in vulnerable populations such as neonates, immunocompromised patients, and the elderly.

• Describe the structural classification and therapeutic role of nystatin within antifungal pharmacotherapy.
• Explain the molecular mechanisms underlying its antifungal activity.
• Outline the pharmacokinetic profile and dosing considerations applicable to various clinical settings.
• Identify common adverse reactions and strategies for monitoring safety.
• Recognize special circumstances in pregnancy, lactation, and organ impairment that necessitate dosage adjustments or alternative therapies.

Classification

Drug Classes and Categories

Nystatin belongs to the polyene antifungal class, characterized by large macrocyclic lactone rings that bind ergosterol within fungal cell membranes. Within this class, nystatin is distinguished by its high affinity for fungal sterols and its limited systemic absorption, which collectively confer a favorable safety profile for topical and oral use. The drug is available in oral suspension, foam, cream, and powder formulations, each designed for specific anatomical sites and patient populations.

Chemical Classification

Structurally, nystatin is a 14-membered macrolide lactone with a glycosidic side chain. Its high molecular weight (~1,200 Da) and hydrophobic character impede passive diffusion across mammalian lipid bilayers, thereby restricting systemic exposure. The molecule contains multiple hydroxyl groups and a carboxylate moiety that contribute to its high binding affinity for ergosterol, facilitating pore formation in fungal membranes.

Mechanism of Action

Pharmacodynamics

Antifungal activity is primarily exerted through high-affinity binding to ergosterol, the principal sterol component of fungal cell membranes. This interaction disrupts membrane integrity, leading to increased permeability and loss of essential ions and metabolites. The resulting ionic imbalance culminates in cellular dysfunction and death. The drug’s potency is largely concentration-dependent, with effective inhibition occurring at micromolar levels against most Candida spp.

Molecular and Cellular Mechanisms

At the molecular level, nystatin intercalates into the lipid bilayer, forming transmembrane channels that allow uncontrolled passage of cations, particularly potassium. The pore formation can be represented by the simplified equation: C(t) = C₀ × e⁻ᵏᵗ, where C₀ denotes initial fungal cell membrane concentration and k represents the rate constant of ergosterol displacement. Additionally, the drug may induce oxidative stress by generating reactive oxygen species within fungal cells, further compromising viability. These combined actions explain the broad-spectrum efficacy against yeast while sparing mammalian cells, which lack ergosterol.

Pharmacokinetics

Absorption

Oral absorption of nystatin is minimal, with less than 1% of the dose entering systemic circulation. This limited bioavailability is attributed to the drug’s large molecular size and hydrophobicity, which inhibit passive intestinal transport. Consequently, the oral suspension is primarily intended for local activity within the gastrointestinal tract, particularly the oral cavity and esophagus. When administered topically, absorption through intact skin is negligible, whereas compromised skin or mucosal surfaces may allow limited uptake.

Distribution

Following ingestion, nystatin remains largely confined to the lumen of the gastrointestinal tract. In the event of minor systemic absorption, distribution is predominantly plasma-bound due to hydrophobic interactions with lipoproteins. The drug does not cross the blood–brain barrier in appreciable amounts. Tissue partitioning is largely restricted to the gut mucosa and, to a lesser extent, the skin.

Metabolism

Metabolic transformation of nystatin is minimal. The drug is largely excreted unchanged, with negligible involvement of hepatic cytochrome P450 enzymes. Therefore, drug–drug interactions mediated through metabolic pathways are uncommon. Minor glucuronidation may occur in specialized cells, yet this does not significantly alter pharmacokinetics.

Excretion

Renal excretion constitutes the principal elimination route. Approximately 80–90% of the orally administered dose is recovered in urine unchanged within 24 hours. The drug’s large size and hydrophilic properties facilitate glomerular filtration, while tubular secretion contributes to the final clearance. Hepatic elimination is negligible, and biliary excretion is not clinically relevant.

Half-life and Dosing Considerations

In patients with normal renal function, the terminal half-life (t_1/2) of nystatin is approximately 2–3 hours. Due to rapid urinary clearance, dosing intervals are typically 8–12 hours for oral suspension. Topical preparations do not require systemic dosing considerations, and local application regimens are guided by clinical response. Dose adjustments are seldom necessary in mild to moderate renal impairment; however, in severe renal dysfunction (eGFR <30 mL/min/1.73 m²), a reduction in dose or an extended interval may be prudent to avoid accumulation of the drug within the gastrointestinal tract.

Therapeutic Uses/Clinical Applications

Approved Indications

Approved indications encompass oral and esophageal candidiasis, cutaneous and mucocutaneous candidiasis, diaper dermatitis, and prophylaxis against Candida colonization in neutropenic patients. The oral suspension is specifically indicated for thrush in patients with a functional gastrointestinal tract, while topical creams and powders address skin and mucosal infections. For neonatal prophylaxis, nystatin powder is often administered orally to reduce Candida colonization in premature infants with low birth weight.

Off-label Uses

Common off-label applications include vaginal candidiasis, where nystatin suppositories may provide localized therapy, and treatment of Candida keratitis, though alternative agents are preferred due to limited ocular penetration. Additionally, some clinicians employ nystatin gel for oral mucositis in patients undergoing chemotherapy, recognizing its low systemic toxicity. The evidence base for these uses is variable, and clinicians should consider alternative agents with superior ocular or systemic efficacy when appropriate.

Adverse Effects

Common Side Effects

Local irritation, burning, or pruritus at the application site are frequently reported when topical formulations are used. Oral suspension may produce transient gastrointestinal discomfort, including nausea, vomiting, or mild abdominal pain. These adverse events are typically self-limiting and resolve upon cessation of therapy. In rare instances, hypersensitivity reactions such as urticaria or angioedema may occur, necessitating discontinuation.

Serious or Rare Reactions

Systemic toxicity is exceedingly uncommon due to minimal absorption. Severe allergic reactions, including anaphylaxis, have been documented but are extremely rare. Cytotoxicity in the gastrointestinal tract is not observed at therapeutic doses. Long-term exposure has not been associated with organ-specific toxicity, although continuous monitoring is advised when used chronically in high-risk populations.

Black Box Warnings

There are no black box warnings associated with nystatin. The drug’s safety profile is well established, and its therapeutic index is considered wide for topical and oral use.

Drug Interactions

Major Drug-Drug Interactions

Because nystatin is not significantly metabolized by cytochrome P450 enzymes, classic enzyme induction or inhibition interactions are rare. However, concurrent use of agents that alter gastrointestinal motility (e.g., prokinetics or anticholinergics) may influence local drug exposure and efficacy. Polymeric binding agents, such as aluminum or magnesium hydroxide, can moderately reduce oral absorption when administered concurrently, though this effect is clinically negligible due to the minimal systemic absorption of nystatin.

Contraindications

Nystatin is contraindicated in patients with a known hypersensitivity to polyene antifungals. Additionally, it should not be used in patients with severe gastrointestinal disease that impairs drug distribution or absorption, such as severe malabsorption syndromes, where local drug concentration may be unpredictable. In neonates, the drug is contraindicated if the infant has a compromised intestinal barrier, as local concentrations may exceed tolerable limits.

Special Considerations

Pregnancy and Lactation

Pregnancy category B suggests that animal studies have not demonstrated a risk to the fetus, but adequate human data are lacking. Nystatin is minimally absorbed systemically, and drug levels in maternal plasma and breast milk remain below therapeutic thresholds. Consequently, it is considered safe for use during pregnancy and lactation, provided that appropriate topical or oral formulations are employed.

Pediatric and Geriatric Use

In pediatric patients, dosing is typically weight-based, ranging from 10,000 to 20,000 IU/kg/day divided into multiple administrations. The drug is generally well tolerated in children, with local irritation being the predominant adverse event. Geriatric patients often have reduced renal clearance; however, given the drug’s limited systemic exposure, dose adjustment is rarely required. Vigilance for potential drug–drug interactions is advisable in older adults on polypharmacy regimens.

Renal and Hepatic Impairment

Renal dysfunction may lead to reduced urinary excretion and transient accumulation of nystatin within the gastrointestinal tract. Clinicians may consider extending dosing intervals or reducing the dose in patients with eGFR <30 mL/min/1.73 m². Hepatic impairment has minimal effect on nystatin pharmacokinetics, and no dose modification is generally necessary. Nonetheless, monitoring for gastrointestinal symptoms remains prudent in patients with advanced liver disease.

Summary/Key Points

• Nystatin is a polyene macrolide with high affinity for fungal ergosterol, leading to pore formation and cellular ionic leakage.
• Its pharmacokinetic profile is characterized by minimal absorption, predominant renal elimination, and a short terminal half-life (~2–3 h).
• Approved indications include oral, cutaneous, and diaper candidiasis, as well as prophylaxis in neutropenic patients; off-label use is common for vaginal and mucosal infections.
• Adverse effects are largely local; systemic toxicity is rare due to limited absorption.
• Drug interactions are uncommon, with no significant enzyme-mediated interactions; caution is advised with agents altering GI motility or binding capacity.
• Special populations—pregnancy, lactation, pediatrics, geriatrics, and renal impairment—typically require no dose adjustment, although monitoring remains essential.
• Clinical pearls: Ensure proper dosing frequency for oral suspension to maintain mucosal drug concentration; consider patient adherence and local tolerability when selecting topical formulations.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.